ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results
ARS Pharmaceuticals (NASDAQ: SPRY), a biopharmaceutical company focused on developing solutions for anaphylaxis protection, has scheduled a conference call and webcast for Wednesday, May 14, 2025, at 5:30 a.m. PT / 8:30 a.m. ET. The event will cover the company's first quarter 2025 financial results and business highlights.
Participants can obtain dial-in information by registering for the event. The webcast and presentation slides will be accessible through the Events & Presentations page in the Investors & Media section of the company's website. A replay will remain available for 30 days after the event.
ARS Pharmaceuticals (NASDAQ: SPRY), un'azienda biofarmaceutica specializzata nello sviluppo di soluzioni per la protezione dall'anafilassi, ha programmato una conference call e una webcast per mercoled矛 14 maggio 2025, alle 5:30 PT / 8:30 ET. L'evento presenter脿 i risultati finanziari del primo trimestre 2025 e i principali aggiornamenti aziendali.
I partecipanti possono ottenere le informazioni per il collegamento telefonico registrandosi all'evento. La webcast e le slide della presentazione saranno disponibili nella pagina Eventi e Presentazioni, nella sezione Investitori e Media del sito web aziendale. La registrazione rester脿 accessibile per 30 giorni dopo l'evento.
ARS Pharmaceuticals (NASDAQ: SPRY), una compa帽铆a biofarmac茅utica enfocada en desarrollar soluciones para la protecci贸n contra la anafilaxia, ha programado una llamada de conferencia y webcast para el mi茅rcoles 14 de mayo de 2025 a las 5:30 a.m. PT / 8:30 a.m. ET. El evento cubrir谩 los resultados financieros del primer trimestre de 2025 y los aspectos destacados del negocio.
Los participantes pueden obtener la informaci贸n para llamar registr谩ndose en el evento. El webcast y las diapositivas de la presentaci贸n estar谩n disponibles en la p谩gina de Eventos y Presentaciones en la secci贸n de Inversores y Medios del sitio web de la compa帽铆a. La repetici贸n estar谩 disponible durante 30 d铆as despu茅s del evento.
ARS Pharmaceuticals (NASDAQ: SPRY)電� 鞎勲倶頃勲澖鞁滌姢 氤错樃 靻旊（靺� 臧滊皽鞐� 欤茧牓頃橂姅 氚旍澊鞓れ牅鞎� 須岇偓搿�, 2025雲� 5鞗� 14鞚� 靾橃殧鞚� 鞓れ爠 5:30 PT / 鞓れ爠 8:30 ET鞐� 旎嵓霟办姢 旖� 氚� 鞗轨簮鞀ろ姼毳� 鞓堨爼頃橁碃 鞛堨姷雼堧嫟. 鞚措矆 頄夓偓鞐愳劀電� 須岇偓鞚� 2025雲� 1攵勱赴 鞛 鞁れ爜瓿� 欤检殧 靷梾 頃橃澊霛检澊韸鸽ゼ 雼る０ 鞓堨爼鞛呺媹雼�.
彀戈皜鞛愲姅 頄夓偓 霌彪鞚� 韱淀暣 鞝勴檾 鞝戩啀 鞝曤炒毳� 氚涭潉 靾� 鞛堨姷雼堧嫟. 鞗轨簮鞀ろ姼鞕� 氚滍憸 鞛愲電� 須岇偓 鞗轨偓鞚错姼鞚� 韴瀽鞛� 氚� 氙鸽敂鞏� 靹轨厴 雮� 鞚措菠韸� 氚� 頂勲爤鞝犿厡鞚挫厴 韼橃澊歆�鞐愳劀 頇曥澑頃� 靾� 鞛堨溂氅�, 頄夓偓臧� 雭濍倻 頉� 30鞚缄皠 雼れ嫓氤搓赴 靹滊箘鞀るゼ 鞝滉车頃╇媹雼�.
ARS Pharmaceuticals (NASDAQ : SPRY), une soci茅t茅 biopharmaceutique sp茅cialis茅e dans le d茅veloppement de solutions de protection contre l'anaphylaxie, a programm茅 une conf茅rence t茅l茅phonique et une webdiffusion pour le mercredi 14 mai 2025 脿 5h30 PT / 8h30 ET. L'茅v茅nement portera sur les r茅sultats financiers du premier trimestre 2025 et les points forts de l'activit茅 de l'entreprise.
Les participants peuvent obtenir les informations d'appel en s'inscrivant 脿 l'茅v茅nement. La webdiffusion et les diapositives de pr茅sentation seront accessibles via la page 脡v茅nements & Pr茅sentations dans la section Investisseurs & M茅dias du site web de la soci茅t茅. Une rediffusion sera disponible pendant 30 jours apr猫s l'茅v茅nement.
ARS Pharmaceuticals (NASDAQ: SPRY), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung von L枚sungen zum Schutz vor Anaphylaxie spezialisiert hat, hat eine Telefonkonferenz und Webcast f眉r Mittwoch, den 14. Mai 2025, um 5:30 Uhr PT / 8:30 Uhr ET angesetzt. Die Veranstaltung wird die Finanzergebnisse des ersten Quartals 2025 und wichtige Gesch盲ftshighlights behandeln.
Teilnehmer k枚nnen die Einwahlinformationen durch Registrierung f眉r die Veranstaltung erhalten. Der Webcast und die Pr盲sentationsfolien sind 眉ber die Seite 鈥濫vents & Presentations鈥� im Bereich 鈥濱nvestoren & Medien鈥� auf der Unternehmenswebsite zug盲nglich. Eine Aufzeichnung wird 30 Tage nach der Veranstaltung verf眉gbar sein.
- None.
- None.
SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Wednesday, May 14, 2025, at 5:30 a.m. PT / 8:30 a.m. ET to discuss its first quarter 2025 financial results and business highlights.
Dial-in information for conference participants may be obtained by . To access the webcast and slides, please visit the page in the Investors & Media section of the Company鈥檚 . A replay of the webcast will be available for 30 days following the event.
About ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing聽neffy庐聽(trade name聽EURneffy庐聽in the EU) (previously referred to as ARS-1), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients 4 years of age and older who weigh 15 kg or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit聽.
Investor Contact:
Justin Chakma, ARS Pharma
[email protected]
Media Contact:
Christy Curran, Sam Brown Inc.
[email protected]
615.414.8668
FAQ
When will ARS Pharmaceuticals (SPRY) report Q1 2025 earnings?
How can I access SPRY's Q1 2025 earnings call?
How long will the replay of ARS Pharmaceuticals' Q1 2025 earnings call be available?
What does ARS Pharmaceuticals (SPRY) specialize in?
